

Part VI: Summary of the risk management plan

Summary of risk management plan for Imatinib CF 100 mg and 400 mg film-coated tablets (Imatinib)

This is a summary of the risk management plan (RMP) for Imatinib CF 100 mg and 400 mg film-coated tablets. The RMP details important risks of Imatinib CF, how this risks can be minimised, and how more information will be obtained about Imatinib CF's risks and uncertainties (missing information). Imatinib CF's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Imatinib CF should be used.

Important new concerns or changes to the current ones will be included in updates of Imatinib CF's RMP.

I. The medicine and what it is used for

Imatinib CF is authorised for the short-term symptomatic relief of sore throat in adults and children over the age of 12 years.

It contains imatinib, as the active substances, and it is given by oral route of administration of Imatinib CF 100 mg and 400 mg film-coated tablets.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Imatinib CF, together with measures to minimise such risks and the proposed studies for learning more about Imatinib CF's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Imatinib CF is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Imatinib CF risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Imatinib CF. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

| Summary of safety concerns | |
|-----------------------------------|---|
| Important identified risks | <ul style="list-style-type: none"> • None |
| Important potential risks | <ul style="list-style-type: none"> • Second primary malignancy • Tolerability during pregnancy and pregnancy outcomes |
| Missing information | <ul style="list-style-type: none"> • Paediatric patients below 2 years of age |

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Imatinib CF.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Applicant's Imatinib CF.